Correlations Between Cytomegalovirus, Epstein-Barr Virus, Anti-ganglioside Antibodies, Electrodiagnostic Findings and Functional Status in Guillain-Barré Syndrome

Overview

Journal Iran J Neurol

Publisher Tehran University of Medical Sciences

Date 2014 May 7

PMID 24800041

Citations 5

Authors

Aliakbar Taheraghdam

Peyman Pourkhanjar

Mahnaz Talebi

Mohammadreza Bonyadi

Ali Pashapour

Ehsan Sharifipour

Reza Rikhtegar

Affiliations

Soon will be listed here.

Abstract

Background: Due to underlying autoimmune background of Guillain-Barré syndrome (GBS), the possible role of infectious agents cytomegalovirus (CMV) and Epstein-Barr virus (EBV) and also due to association of anti-ganglioside antibodies with GBS, the present study aimed to investigate the associations between serum anti-ganglioside antibodies (AGA) level, type of infection and electrodiagnostic (ED) findings with the severity and three-month functional outcome of patients with GBS.

Methods: In a prospective study, 30 patients with GBS were selected and before starting the treatment, baseline serum samples of patients were obtained for measuring the serum AGA including the antibodies against GQ1b, GT1b, GD1a, GD1b, GM1, GM2, GM3 and strains of CMV and EBV. All the patients were precisely examined for ED findings. Functional status of patients on admission and three months after admission were recorded according to the modified Rankin scale (mRS).

Results: The results of patients' serum assessment revealed that CMV IgM was positive in one patient (3.3%), CMV IgG in 29 patients (96.7%) and EBV IgG in 27 patients (90%). Anti-GM1 was found in 3 patients (10%) and anti-GM3 was found only in one patient (3.3%). However, no statistical significant association was found between the AGA and strain of the disease and ED findings.

Conclusion: Despite the coexistence of AGA and serum antibodies against CMV and EBV in some GBS patients, there was not clear association in this regard. However, the AGA was positive in patients who suffered from severe phase of the disease.

Citing Articles

An Unusual Presentation of Generalized Tetanus Following Post-Exposure Vaccination Complicated by Acute Motor Sensory Axonal Neuropathy: A Case Report.

Wickramathunga C, Anpalahan P, Thivakaran T, Silva S Cureus. 2024; 16(10):e72734.

PMID: 39618564 PMC: 11606731. DOI: 10.7759/cureus.72734.

Immunotherapy of Guillain-Barré syndrome.

Liu S, Dong C, Ubogu E Hum Vaccin Immunother. 2018; 14(11):2568-2579.

PMID: 29953326 PMC: 6314401. DOI: 10.1080/21645515.2018.1493415.

Association of anti-gangliosides antibodies and anti-CMV antibodies in Guillain-Barré syndrome.

Wang L, Shao C, Yang C, Kang X, Zhang G Brain Behav. 2017; 7(5):e00690.

PMID: 28523231 PMC: 5434194. DOI: 10.1002/brb3.690.

Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals.

Patel P, Kearney J J Immunol. 2016; 197(11):4201-4209.

PMID: 27864551 PMC: 5119654. DOI: 10.4049/jimmunol.1600872.

The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.

Ziganshin R, Ivanova O, Lomakin Y, Belogurov Jr A, Kovalchuk S, Azarkin I Mol Cell Proteomics. 2016; 15(7):2366-78.

PMID: 27143409 PMC: 4937510. DOI: 10.1074/mcp.M115.056036.

References

Rajabally Y, Uncini A . Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012; 83(7):711-8. DOI: 10.1136/jnnp-2011-301882. View

Capasso M, Notturno F, Manzoli C, Uncini A . Involvement of sensory fibres in axonal subtypes of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2011; 82(6):664-70. DOI: 10.1136/jnnp.2010.238311. View

Nafissi S, Vahabi Z, Sadeghi Ghahar M, Amirzargar A, Naderi S . The role of cytomegalovirus, Haemophilus influenzae and Epstein Barr virus in Guillain Barre syndrome. Acta Med Iran. 2013; 51(6):372-6. View

Jacobs B, van Doorn P, Groeneveld J, Tio-Gillen A, van der Meche F . Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1997; 62(6):641-3. PMC: 1074154. DOI: 10.1136/jnnp.62.6.641. View

Hughes R, Rees J . Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997; 176 Suppl 2:S92-8. DOI: 10.1086/513793. View

Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R . Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry. 1999; 66(3):376-9. PMC: 1736267. DOI: 10.1136/jnnp.66.3.376. View

Uncini A, Manzoli C, Notturno F, Capasso M . Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010; 81(10):1157-63. DOI: 10.1136/jnnp.2010.208538. View

van Doorn P, Ruts L, Jacobs B . Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008; 7(10):939-50. DOI: 10.1016/S1474-4422(08)70215-1. View

Meulstee J, van der Meche F . Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry. 1995; 59(5):482-6. PMC: 1073708. DOI: 10.1136/jnnp.59.5.482. View

10.

Kornberg A, Pestronk A, Bieser K, Ho T, McKhann G, Wu H . The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol. 1994; 35(2):234-7. DOI: 10.1002/ana.410350217. View

11.

Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, Obayashi H . Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol. 1998; 81(1-2):116-26. DOI: 10.1016/s0165-5728(97)00166-5. View

12.

Jacobs B, Meulstee J, van Doorn P, van der Meche F . Electrodiagnostic findings related to anti-GM1 and anti-GQ1b antibodies in Guillain-Barré syndrome. Muscle Nerve. 1997; 20(4):446-52. DOI: 10.1002/(sici)1097-4598(199704)20:4<446::aid-mus7>3.0.co;2-a. View

13.

Seneviratne U . Guillain-Barré syndrome. Postgrad Med J. 2000; 76(902):774-82. PMC: 1741839. DOI: 10.1136/pmj.76.902.774. View

14.

Yuki N, Yoshino H, Sato S, Miyatake T . Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990; 40(12):1900-2. DOI: 10.1212/wnl.40.12.1900. View

15.

Ledeen R, Yu R . Gangliosides: structure, isolation, and analysis. Methods Enzymol. 1982; 83:139-91. DOI: 10.1016/0076-6879(82)83012-7. View

16.

Sivadon V, Orlikowski D, Rozenberg F, Quincampoix J, Caudie C, Durand M . [Prevalence and characteristics of Guillain-Barré syndromes associated with Campylobacter jejuni and cytomegalovirus in greater Paris]. Pathol Biol (Paris). 2005; 53(8-9):536-8. DOI: 10.1016/j.patbio.2005.06.006. View

17.

Ang C, Jacobs B, Laman J . The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004; 25(2):61-6. DOI: 10.1016/j.it.2003.12.004. View

18.

Prendergast M, Moran A . Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J Endotoxin Res. 2001; 6(5):341-59. View

19.

van der Meche F, Meulstee J, Vermeulen M, Kievit A . Patterns of conduction failure in the Guillain-Barré syndrome. Brain. 1988; 111 ( Pt 2):405-16. DOI: 10.1093/brain/111.2.405. View

20.

Asbury A, Cornblath D . Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990; 27 Suppl:S21-4. DOI: 10.1002/ana.410270707. View